RLAY Relay Therapeutics, Inc.

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

$27.52  -0.09 (-0.33%)
As of 05/13/2021 15:59:38 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/16/2020
Outstanding shares:  90,399,972
Average volume:  581,847
Market cap:   $2,504,983,224
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75943R102
ISIN:        US75943R1023
Sedol:      BN2R582
Valuation   (See tab for details)
PE ratio:   72.78
PB ratio:   3.36
PS ratio:   30.31
Return on equity:   -6.87%
Net income %:   -63.41%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy